 AVEO Oncology Nasdaq: AVEO today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of 5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately 51.1 million, before deducting underwriting discounts and commissions and offering expenses payable by AVEO. 